{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:19:39Z","timestamp":1780586379727,"version":"3.54.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s13311-019-00825-1","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T14:04:17Z","timestamp":1577369057000},"page":"142-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-5661","authenticated-orcid":false,"given":"Stephen M.","family":"Chrzanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seward B.","family":"Rutkove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-019-00825-1_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings","volume":"1","author":"Bushby","year":"2011","journal-title":"Clin. Investig."},{"key":"10.1007\/s13311-019-00825-1_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell."},{"key":"10.1007\/s13311-019-00825-1_bib3","first-page":"163","article-title":"A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies. Can. J. Neurol. Sci. J. Can. Sci","volume":"43","author":"Mah","year":"2016","journal-title":"Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib7","unstructured":"Duchenne G-B. Physiologie des mouvements d\u00e9montr\u00e9e \u00e0 l'aide de l'experimentation \u00e9lectrique et de l'observation clinique: et applicable \u00e0 l'\u00e9tude des paralysies et des d\u00e9formations. Bailli\u00e8re; 1867."},{"key":"10.1007\/s13311-019-00825-1_bib8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","article-title":"Membrane organization of the dystrophin-glycoprotein complex","volume":"66","author":"Ervasti","year":"1991","journal-title":"Cell."},{"key":"10.1007\/s13311-019-00825-1_bib9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2010.11.039","article-title":"Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx\/mTR mice","volume":"143","author":"Sacco","year":"2010","journal-title":"Cell."},{"key":"10.1007\/s13311-019-00825-1_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1113\/jphysiol.2006.118265","article-title":"Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo","volume":"578","author":"Tidball","year":"2007","journal-title":"J. Physiol."},{"key":"10.1007\/s13311-019-00825-1_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/jhg.2013.119","article-title":"Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients","volume":"59","author":"Lee","year":"2014","journal-title":"J. Hum. Genet."},{"key":"10.1007\/s13311-019-00825-1_bib12","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary Cardiac Issues in Duchenne Muscular Dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation."},{"key":"10.1007\/s13311-019-00825-1_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0960-8966(96)00357-4","article-title":"Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy","volume":"6","author":"Melacini","year":"1996","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib14","doi-asserted-by":"crossref","first-page":"e11381","DOI":"10.1097\/MD.0000000000011381","article-title":"Natural history of cardiac function in Duchenne and Becker muscular dystrophies on home mechanical ventilation","volume":"97","author":"Fayssoil","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1007\/s13311-019-00825-1_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/jhg.2016.7","article-title":"Genetic diagnosis of Duchenne\/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations","volume":"61","author":"Okubo","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1007\/s13311-019-00825-1_bib16","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","article-title":"Long-term benefit from prednisone therapy in Duchenne muscular dystrophy","volume":"41","author":"Fenichel","year":"1991","journal-title":"Neurology."},{"key":"10.1007\/s13311-019-00825-1_bib17","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1007\/s13311-019-00825-1_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2106\/JBJS.L.01577","article-title":"Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up","volume":"95","author":"Lebel","year":"2013","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1007\/s13311-019-00825-1_bib19","doi-asserted-by":"crossref","unstructured":"Kinnett K, Noritz G. The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression. PLoS Curr. 2017;9.","DOI":"10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e"},{"key":"10.1007\/s13311-019-00825-1_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1007\/s13311-019-00825-1_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib24","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs."},{"key":"10.1007\/s13311-019-00825-1_bib25","doi-asserted-by":"crossref","unstructured":"Goemans NM, Tulinius M, van den Hauwe M, et al. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. PLoS ONE [Internet]. 2016;11. Available from:https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5010191\/.","DOI":"10.1371\/journal.pone.0161955"},{"key":"10.1007\/s13311-019-00825-1_bib26","doi-asserted-by":"crossref","unstructured":"Ricotti V, Spinty S, Roper H, et al. Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy. PLoS ONE [Internet]. 2016;11. Available from:https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4824384\/.","DOI":"10.1371\/journal.pone.0152840"},{"key":"10.1007\/s13311-019-00825-1_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","article-title":"Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study","volume":"77","author":"Mazzone","year":"2011","journal-title":"Neurology."},{"key":"10.1007\/s13311-019-00825-1_bib28","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat. Med."},{"key":"10.1007\/s13311-019-00825-1_bib29","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. 2014."},{"key":"10.1007\/s13311-019-00825-1_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and Surrogate Markers: An FDA Perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx."},{"key":"10.1007\/s13311-019-00825-1_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/psp4.12220","article-title":"Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test","volume":"6","author":"Hamuro","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1007\/s13311-019-00825-1_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/1756-0500-7-269","article-title":"Comparison of walking performance over the first 2 minutes and the full 6 minutes of the Six-Minute Walk Test","volume":"7","author":"Bohannon","year":"2014","journal-title":"BMC Res. Notes."},{"key":"10.1007\/s13311-019-00825-1_bib33","doi-asserted-by":"crossref","first-page":"e0164684","DOI":"10.1371\/journal.pone.0164684","article-title":"Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy","volume":"11","author":"Goemans","year":"2016","journal-title":"PloS One."},{"key":"10.1007\/s13311-019-00825-1_bib34","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PloS One."},{"key":"10.1007\/s13311-019-00825-1_bib35","first-page":"151","article-title":"Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy. Acta Myol. Myopathies Cardiomyopathies Off. J. Mediterr. Soc","volume":"36","author":"Chrzanowski","year":"2017","journal-title":"Myol."},{"key":"10.1007\/s13311-019-00825-1_bib36","first-page":"258","article-title":"miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol","volume":"3","author":"Cacchiarelli","year":"2011","journal-title":"Med."},{"key":"10.1007\/s13311-019-00825-1_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/nbm.2851","article-title":"T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy","volume":"26","author":"Arpan","year":"2013","journal-title":"NMR Biomed."},{"key":"10.1007\/s13311-019-00825-1_bib38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1212\/WNL.0000000000000775","article-title":"Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS","volume":"83","author":"Arpan","year":"2014","journal-title":"Neurology."},{"issue":"Suppl 2","key":"10.1007\/s13311-019-00825-1_bib39","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.nmd.2012.08.001","article-title":"Applications of MRI in muscle diseases","volume":"22","author":"Carlier","year":"2012","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1007\/s13311-019-00825-1_bib40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/nbm.3352","article-title":"Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy","volume":"28","author":"Wary","year":"2015","journal-title":"NMR Biomed."},{"key":"10.1007\/s13311-019-00825-1_bib41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000002464","article-title":"Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy","volume":"86","author":"Hogrel","year":"2016","journal-title":"Neurology."},{"key":"10.1007\/s13311-019-00825-1_bib42","doi-asserted-by":"crossref","first-page":"e106435","DOI":"10.1371\/journal.pone.0106435","article-title":"Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study","volume":"9","author":"Forbes","year":"2014","journal-title":"PLoS ONE."},{"key":"10.1007\/s13311-019-00825-1_bib43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.apmr.2010.03.024","article-title":"Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy","volume":"91","author":"Mathur","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1007\/s13311-019-00825-1_bib44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0960-8966(02)00023-8","article-title":"Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1)","volume":"12","author":"Mercuri","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1007\/s13311-019-00825-1_bib45","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00415-017-8547-3","article-title":"Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy","volume":"264","author":"Burakiewicz","year":"2017","journal-title":"J. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2017.02.009","article-title":"Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy","volume":"27","author":"Hooijmans","year":"2017","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00415-012-6733-x","article-title":"Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy","volume":"260","author":"Fischmann","year":"2013","journal-title":"J. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1148\/radiol.13121948","article-title":"Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy","volume":"269","author":"Forbes","year":"2013","journal-title":"Radiology."},{"key":"10.1007\/s13311-019-00825-1_bib49","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00256-011-1301-5","article-title":"Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments","volume":"41","author":"Gaeta","year":"2012","journal-title":"Preliminary experience. Skeletal Radiol."},{"key":"10.1007\/s13311-019-00825-1_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00415-016-8311-0","article-title":"Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy","volume":"264","author":"Willcocks","year":"2017","journal-title":"J. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jmri.23998","article-title":"Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients","volume":"38","author":"Wokke","year":"2013","journal-title":"J. Magn. Reson. Imaging."},{"key":"10.1007\/s13311-019-00825-1_bib52","doi-asserted-by":"crossref","first-page":"W8","DOI":"10.2214\/AJR.07.2732","article-title":"Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study","volume":"190","author":"Wren","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1007\/s13311-019-00825-1_bib53","doi-asserted-by":"crossref","first-page":"e0182086","DOI":"10.1371\/journal.pone.0182086","article-title":"Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up","volume":"12","author":"Hooijmans","year":"2017","journal-title":"PloS One."},{"key":"10.1007\/s13311-019-00825-1_bib54","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1152\/japplphysiol.01021.2010","article-title":"Muscle damage alters the metabolic response to dynamic exercise in humans: a 31P-MRS study","volume":"111","author":"Davies","year":"2011","journal-title":"J. Appl. Physiol."},{"key":"10.1007\/s13311-019-00825-1_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0960-8966(97)00108-9","article-title":"Correlative MR imaging and 31P-MR spectroscopy study in sarcoglycan deficient limb girdle muscular dystrophy","volume":"7","author":"Lodi","year":"1997","journal-title":"Neuromuscul. Disord."},{"key":"10.1007\/s13311-019-00825-1_bib56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2014.03.013","article-title":"Assessment of intramuscular lipid and metabolites of the lower leg using magnetic resonance spectroscopy in boys with Duchenne muscular dystrophy","volume":"24","author":"Lott","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1007\/s13311-019-00825-1_bib57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","article-title":"Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: Effects of age and disease progression","volume":"24","author":"Willcocks","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1007\/s13311-019-00825-1_bib58","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1148\/radiol.10091547","article-title":"T2 Mapping in Duchenne Muscular Dystrophy: Distribution of Disease Activity and Correlation with Clinical Assessments1","volume":"255","author":"Kim","year":"2010","journal-title":"Radiology."},{"key":"10.1007\/s13311-019-00825-1_bib59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.nmd.2017.04.008","article-title":"Skeletal muscle water T2as a biomarker of disease status and exercise effects in patients with Duchenne muscular dystrophy","volume":"27","author":"Mankodi","year":"2017","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fneur.2018.00009","article-title":"Semi-Automated Analysis of Diaphragmatic Motion with Dynamic Magnetic Resonance Imaging in Healthy Controls and Non-Ambulant Subjects with Duchenne Muscular Dystrophy","volume":"9","author":"Bishop","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib61","doi-asserted-by":"crossref","first-page":"e0194283","DOI":"10.1371\/journal.pone.0194283","article-title":"Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy","volume":"13","author":"Barnard","year":"2018","journal-title":"PloS One."},{"key":"10.1007\/s13311-019-00825-1_bib62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort","volume":"79","author":"Willcocks","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.nmd.2015.05.006","article-title":"Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy","volume":"25","author":"Bonati","year":"2015","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib64","doi-asserted-by":"crossref","unstructured":"Rutkove SB, Darras BT. Electrical impedance myography for the assessment of children with muscular dystrophy: a preliminary study. J. Phys. Conf. Ser. 2013;434.","DOI":"10.1088\/1742-6596\/434\/1\/012069"},{"key":"10.1007\/s13311-019-00825-1_bib65","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.24874","article-title":"Electrical impedance myography for assessment of Duchenne muscular dystrophy","volume":"81","author":"Rutkove","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pediatrneurol.2014.02.015","article-title":"Cross-sectional Evaluation of Electrical Impedance Myography and Quantitative Ultrasound for the Assessment of Duchenne Muscular Dystrophy in a Clinical Trial Setting","volume":"51","author":"Rutkove","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib67","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mus.24611","article-title":"Electrical impedance myography in Duchenne muscular dystrophy and healthy controls: A multicenter study of reliability and validity","volume":"52","author":"Zaidman","year":"2015","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib68","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mus.21784","article-title":"Characterizing Spinal Muscular Atrophy with Electrical Impedance Myography","volume":"42","author":"Rutkove","year":"2010","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1007\/s13311-019-00825-1_bib70","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/mus.20377","article-title":"Electrical impedance myography in the detection of radiculopathy","volume":"32","author":"Rutkove","year":"2005","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib71","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/mus.25065","article-title":"Electrical impedance myography in facioscapulohumeral muscular dystrophy","volume":"54","author":"Statland","year":"2016","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mus.10048","article-title":"Localized bioimpedance analysis in the evaluation of neuromuscular disease","volume":"25","author":"Rutkove","year":"2002","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/17482968.2012.688837","article-title":"Electrical impedance myography as a biomarker to assess ALS progression","volume":"13","author":"Rutkove","year":"2012","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1007\/s13311-019-00825-1_bib74","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.clinph.2007.08.004","article-title":"Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials","volume":"118","author":"Rutkove","year":"2007","journal-title":"Clin. Neurophysiol."},{"key":"10.1007\/s13311-019-00825-1_bib75","doi-asserted-by":"crossref","unstructured":"Shefner JM, Rutkove SB, Caress JB, et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph. Lateral Scler. Front. Degener. 2018;1\u20137.","DOI":"10.1080\/21678421.2018.1510008"},{"key":"10.1007\/s13311-019-00825-1_bib76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1109\/TBCAS.2015.2456242","article-title":"A Batteryless Sensor ASIC for Implantable Bio-Impedance Applications","volume":"10","author":"Rodriguez","year":"2016","journal-title":"IEEE Trans. Biomed. Circuits Syst."},{"key":"10.1007\/s13311-019-00825-1_bib77","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/mus.21015","article-title":"Muscle ultrasound in neuromuscular disorders","volume":"37","author":"Pillen","year":"2008","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib78","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(80)92656-2","article-title":"Detection of pathological change in dystrophic muscle with B-scan ultrasound imaging","volume":"1","author":"Heckmatt","year":"1980","journal-title":"Lancet Lond. Engl."},{"key":"10.1007\/s13311-019-00825-1_bib79","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.nmd.2010.06.019","article-title":"Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy","volume":"20","author":"Zaidman","year":"2010","journal-title":"Neuromuscul. Disord. NMD."},{"key":"10.1007\/s13311-019-00825-1_bib80","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mus.24609","article-title":"Muscle ultrasound quantifies disease progression over time in infants and young boys with duchenne muscular dystrophy","volume":"52","author":"Zaidman","year":"2015","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-019-00825-1_bib81","first-page":"306","article-title":"Nijhuis van der Sanden MWG, et al. Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne muscular dystrophy. Neuromuscul. Disord","volume":"22","author":"Jansen","year":"2012","journal-title":"NMD."},{"key":"10.1007\/s13311-019-00825-1_bib82","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jbiomech.2017.01.008","article-title":"Shear wave elastography of the supraspinatus muscle and tendon: Repeatability and preliminary findings","volume":"53","author":"Baumer","year":"2017","journal-title":"J. Biomech."},{"key":"10.1007\/s13311-019-00825-1_bib83","unstructured":"Food and Drug Administration C for DE and. Development & Approval Process (Drugs) - Drug Development Tools: Fit-for-Purpose Initiative [Internet]. [cited 2019 Mar 3]. Available from:https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/ucm505485.htm."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00825-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:00:18Z","timestamp":1761807618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923013843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1878747923013843"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00825-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00825-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}